Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Xuanzhu Biopharmaceutical Co., Ltd. Class H (2575) Stock Price & Analysis

2575 Stock Chart & Stats

HK$7.73-HK$0.87(-10.12%)
At close: 4:08 PM GMT+8
HK$8HK$10HK$123 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
HKD 8.55 - HKD 9.01
52-Week Range
HKD 8.01 - HKD 96.90
Previous Close
HKD 8.55
Volume
N/A
Average Volume (3M)
2.02M
Market Cap
HKD 4.45B
Enterprise Value
HKD 6.24B
Total Cash (Recent Filing)
HKD 587.30M
Total Debt (Recent Filing)
HKD 251.80K
Price to Earnings (P/E)
―
Beta
2.12
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Strong TTM revenue growth indicates expanding commercial traction and improving product adoption. If sustained, this momentum can broaden the company’s revenue base, support operating leverage, and provide a foundation for eventual profitability as the business scales.

Gross Margin Improvement

The sharp gross-margin improvement points to materially better product economics and suggests that revenue growth is becoming more valuable to the business. Maintaining this improvement would increase the contribution available to fund research, selling costs, and progress toward breakeven.

Very Low Leverage

Extremely low leverage gives the company a conservatively financed balance sheet and limits interest-related pressure on future cash flows. Equity funding most assets also preserves financial flexibility to support operations or pursue growth without substantial debt-service obligations.

Bears Say

Deeply Negative Profitability

A net margin near negative 201% shows that strong revenue growth has not yet translated into an economically sustainable business model. Continued losses can restrict internally funded investment, require additional financing, and delay the point at which growth begins creating shareholder value.

Persistent Cash Burn

Materially negative operating and free cash flow means the company is consuming cash while running the business rather than funding itself. Continued burn reduces financial resilience over the next several quarters and could force management to seek external capital to sustain development and commercial expansion.

Unproven Cost Scalability

Consistent historical losses indicate that improved revenue and gross margin have not yet produced adequate operating leverage. Until expenses scale more slowly than revenue, additional commercial growth may continue increasing funding needs instead of converting into durable earnings and cash generation.

Xuanzhu Biopharmaceutical Co., Ltd. Class H News

2575 FAQ

What was Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price range in the past 12 months?
Xuanzhu Biopharmaceutical Co., Ltd. Class H lowest stock price was HK$8.01 and its highest was HK$96.90 in the past 12 months.
What is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s market cap?
Xuanzhu Biopharmaceutical Co., Ltd. Class H’s market cap is HK$4.45B.
When is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Xuanzhu Biopharmaceutical Co., Ltd. Class H’s earnings last quarter?
Xuanzhu Biopharmaceutical Co., Ltd. Class H released its earnings results on Aug 26, 2026. The company reported -HK$0.166 earnings per share for the quarter.
Is Xuanzhu Biopharmaceutical Co., Ltd. Class H overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Xuanzhu Biopharmaceutical Co., Ltd. Class H pay dividends?
Xuanzhu Biopharmaceutical Co., Ltd. Class H does not currently pay dividends.
What is Xuanzhu Biopharmaceutical Co., Ltd. Class H’s EPS estimate?
Xuanzhu Biopharmaceutical Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xuanzhu Biopharmaceutical Co., Ltd. Class H have?
Xuanzhu Biopharmaceutical Co., Ltd. Class H has 517,947,800 shares outstanding.
What happened to Xuanzhu Biopharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?
Xuanzhu Biopharmaceutical Co., Ltd. Class H reported an EPS of -HK$0.166 in its last earnings report. Following the earnings report the stock price went up 2.093%.
Which hedge fund is a major shareholder of Xuanzhu Biopharmaceutical Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2575
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology